ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.
Also called NCT03004703
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT03004703 -
2016-002581-31
-
- Other papers using this trial's data
- Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab
- Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Norway
- Registry status
- Completed
Technical summary
Registry record NCT03004703. Randomized; quadruple masking; primary purpose treatment. Start 2017-03-16 (actual); primary completion 2020-02-19 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial
- Acronym
- ASSAIL-MI
- Condition
- Coronary Disease
- Condition
- Myocardial Infarction
- Intervention (Drug)
- Tocilizumab
- Intervention (Drug)
- Sodium chloride 0.9%
- Lead sponsor
- Oslo University Hospital
- Collaborator
- St. Olavs Hospital
- Collaborator
- South-Eastern Norway Regional Health Authority
- Collaborator
- University of Oslo
- Collaborator
- Norwegian University of Science and Technology
Record details
- Record id
cardio:ct-nct03004703- Content hash
beac90567a7d4d1e6b299e7415559710bf575d30cd76688bee0624ce1efa789d